Prospects for xenotransplantation of the liver

Seminars in Liver Disease

Volumn 20, Issue 4, 2000, Pages 511-522

  Harland, Robert C ^a   Platt, Jeffrey L ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Immunology; Liver; Xenotransplantation

Indexed keywords

BLOOD GROUP ANTIBODY;

ANTIGEN ANTIBODY COMPLEX; ARTICLE; BLOOD GROUP ABO INCOMPATIBILITY; CELL TRANSPLANTATION; CLASSIFICATION; EXTRACORPOREAL CIRCULATION; GRAFT REJECTION; HEPATITIS; HUMAN; IMMUNE COMPLEX DEPOSITION; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION; LIVER CELL; LIVER PERFUSION; LIVER TRANSPLANTATION; NONHUMAN; ORGAN DONOR; PRIMATE; PRIORITY JOURNAL; RECURRENT DISEASE; SENSITIZATION; SWINE; TREATMENT INDICATION; XENOTRANSPLANTATION;

ANIMALS; GRAFT REJECTION; HEPATOCYTES; HUMANS; LIVER; LIVER TRANSPLANTATION; PERFUSION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0034523298     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13159     Document Type: Article

References (78)

1. The UNOS OPTN waiting list and donor registry
2. Baboon-to-human liver transplantation
3. Muscle-mediated gene therapy
4. New directions for organ transplantation
5. Renal heterotransplantation in man
6. Xenotransplantation at a crossroads: Prevention versus progress
7. Xenografting: Probability, possibility, or pipe dream?
8. Use of transgenic animals in xenotransplanration
9. Liver transplantation
10. Indications for and timing of liver transplantation
11. Prospects of clinical xenotransplantation
12. Clinical xenotransplantation - A brief review of the world experience
13. Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction
14. Clinical heterotransplantation of the liver
15. Liver transplantation
16. Clinical trials and projected future of liver xenotransplantation
17. The use of a pig liver xenograft for temporary support of a patient with fulminant hepatic failure
18. Auxiliary partial orthotopic liver transplantation for Crigler-Najjar syndrome type I
19. Hepatocyte transplantation: A potential treatment for acute liver failure
20. Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes
21. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation
22. Hepatocyte Transplantation
23. Reduction of serum cholesterol in watanabe rabbits by xenogeneic hepatocellular transplantation
24. Hepatocyte transplantation: History, immunology, and potential for clinical application
25. Xenogeneic cell therapy: Current progress and future developments in porcine cell transplantation
26. Correction of congenital hyperbilirubinemia in homozygous Gunn rats by xenotransplantation of hamster livers
27. Treatment of hepatic coma by extracorporeal pig-liver perfusion
28. Treatment of hepatic failure with ex vivo pig-liver perfusion followed by liver transplantation
29. Extracorporeal xenogeneic liver perfusion for the treatment of hepatic failure
30. Clinical experience with a bioartifical liver in the treatment of severe liver failure. A phase 1 clinical trial
31. Treatment of severe liver failure with a bioartificial liver
32. What should we expect from a bioartificial liver in fulminant hepatic failure?
33. Hyperacute xenograft rejection
34. Immunopathology of hyperacute xenograft rejection in a swine-to-primate model
35. Evolutionary relationship between the natural anti-Gal antibody and the Galα1-3Gal epitope in primates
36. Variation in expression of porcine xenogeneic antigens
37. Hepatic allografts and xenografts in primates
38. Mechanisms of injury in porcine livers perfused with blood of humans with fulminant hepatic failure
39. Hepatic transplantation into sensitized recipients: Demonstration of hyperacute rejection
40. Hyperacute rejection in porcine liver transplantation: I. Clinical characteristics, histopathology, and disappearance of donor-specific lymphocytotoxic antibody from serum
41. The role of natural anti-Galα1-3Gal antibodies in hyperacute rejection of pig-to-baboon cardiac xenotransplants
42. Prolongation of cardiac xenograft survival by depletion of complement
43. The effect of soluble complement receptor type 1 on hyperacute rejection of porcine xenografts
44. Immunoglobulin prevents complement mediated hyperacute rejection in swine-to-primate xenotransplantation
45. Transplantation of discordant xenografts: A review of progress
46. Transgenic swine as a recombinant production system for human hemoglobin
47. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury
48. Transgenic pigs expressing human CD59 and decay-accelerating factor produce an intrinsic barrier to complement-mediated damage
49. Effect of transgenic expression of human decay-accelerating factor on the inhibition of hyperacute rejection of pig organs
50. Inhibition of complement-mediated endothelial cell cytotoxicity by decay accelerating factor: Potential for prevention of xenograft hyperacute rejection
51. Enzymatic remodelling of the carbohydrate surface of a xenogeneic cell substantially reduces human antibody binding and complement-mediated cytolysis
52. Oocyte Gala 1, 3Gal epitopes implicated in sperm adhesion to the zona pellucida glycoprotein ZP3 are not required for fertilization in the mouse
53. The immunopathology of cardiac xenograft rejection in the guinea pig-to-rat model
54. Renal transplantation
55. Liver transplantation across ABO blood group barriers
56. Acute vascular rejection
57. Delayed xenograft rejection
58. Molecular barriers to xenotransplantation
59. The role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants
60. ABO-incompatible renal transplantation: Initial immunopathologic evaluation
61. ABO incompatible renal transplantation: A qualitative analysis of native endothelial tissue ABO antigens after transplant
62. Transplantation of discordant xenografts: A challenge revisited
63. Protective genes expressed in endothelial cells: A regulatory response to injury
64. Tolerance across discordant xenogeneic barriers
65. Cross-species transplantation tolerance: Rat bone marrow-derived cells can contribute to the ligand for negative selection of mouse T cell receptor Vb in chimeras tolerant to xenogeneic antigens (mouse + rat → mouse)
66. Skin graft tolerance across a discordant xenogeneic barrier
67. Early recognition of a discordant xenogeneic organ by human circulating lymphocytes
68. Cell migration, chimerism, and graft acceptance
69. Evidence of immunocomplex formation in pulmonary xenografts
70. Xenotransplantation: Prospects for clinical application
71. Total respiratory support from swine lungs in primate recipients
72. The evaluation of thrombomodulin activity in porcine to human xenotransplantation
73. Complement activation by xenogeneic red blood cells
74. Detoxifying activity in pig livers and hepatocytes intended for xenotherapy
75. Infection of human cells by an endogenous retrovirus of pigs
76. No evidence of pig DNA or retroviral infection in patients with short-term extracorporeal connection to pig kidneys
77. Search for cross-species transmission of porcine endogenous retrovirus in patients treated with living pig tissue
78. Xenoassistance devices" for the treatment of hepatic failure: Challenges and controversies